![](/img/cover-not-exists.png)
A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected Patients
Wood, R., Eron, J., Arasteh, K., Teofilo, E., Trepo, C., Livrozet, J.-M., Yeo, J., Millard, J., Wire, M. B., Naderer, O. J.Volume:
39
Language:
english
Journal:
Clinical Infectious Diseases
DOI:
10.1086/422452
Date:
August, 2004
File:
PDF, 76 KB
english, 2004